Taniborbactam Hydrochloride

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H28BN3O5.2ClH
Molecular Weight	462.176
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Taniborbactam Hydrochloride

Structure Search

SMILES

Cl.Cl.NCCN[C@H]1CC[C@H](CC(=O)N[C@H]2CC3=CC=CC(C(O)=O)=C3OB2O)CC1

InChI

InChIKey=CKWIMFZHNCBHIX-DKZBTPFISA-N

InChI=1S/C19H28BN3O5.2ClH/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27;;/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26);2*1H/t12-,14-,16-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C19H28BN3O5
Molecular Weight	389.254
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29150844 | https://www.ncbi.nlm.nih.gov/pubmed/29571573

N-(4-Ethylphenyl)-3-(Hydroxymethyl)-N-Isobutyl-4-(Tetrahydro-2h-Pyran-4-Ylmethoxy)Benzenesulfonamide (also known as GSK2981278) is a highly potent and selective inverse agonist of RORγ under development for the topical treatment of psoriasis. Preclinical data showed that GSK2981278 significantly inhibited the production of the Th17 signature cytokines in multiple in vitro and human tissue‐based systems. GSK2981278 may block the transcriptional activity of RORγt, leading to local suppression of cytokine expression and ultimately, improvement in psoriasis. Unfortunately in phase I clinical trial clinical assessment results showed no improvement of psoriatic lesions following treatment with GSK2981278.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Nuclear receptor ROR-gamma 3 Target ID: P51449 Gene ID: 6097.0 Gene Symbol: RORC Target Organism: Homo sapiens (Human) Sources: https://www.gsk-clinicalstudyregister.com/study/201465#ps \| https://www.ncbi.nlm.nih.gov/pubmed/26870941	Inverse Agonist 80

PubMed

Title	Date	PubMed
A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.	2018 Jun	29150844

Patents

Sample Use Guides

In Vivo Use Guide

Participants were treated with 200 mkL of GSK2981278 ointment (0.03%, 0.1%, 0.8% or 4%),

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:37:22 GMT 2023` Edited by `admin` on `Sat Dec 16 12:37:22 GMT 2023`
Record UNII	4VND3V607A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Taniborbactam Hydrochloride

Official Name

English

2H-1,2-Benzoxaborin-8-carboxylic acid, 3-[[2-[trans-4-[(2-aminoethyl)amino]cyclohexyl]acetyl]amino]-3,4-dihydro-2-hydroxy-, hydrochloride (1:2), (3R)-

Systematic Name

English

TANIBORBACTAM DIHYDROCHLORIDE

Common Name

English

TANIBORBACTAM HYDROCHLORIDE [USAN]

Common Name

English

VNRX-5133 DIHYDROCHLORIDE

Code

English

VNRX5133 DIHYDROCHLORIDE

Code

English

(3R)-3-(2-{trans-4-[(2-aminoethyl)amino]cyclohexyl}acetamido)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborine-8-carboxylic acid hydrochloride (1:2)

Systematic Name

English

Code System Code Type Description

USAN

HI-20